SEC Filing Summary: SIGA Technologies Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SIGA Technologies, Inc. on September 22, 2005. The report discloses the entry into a material definitive agreement with the United States Army Medical Research and Material Command (USAMRMC).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial disclosure is the value of the new contract:
- Contract Value: $3.2 million
- Contract Duration: One year
- Funding Source: United States Air Force (USAF)
Material Changes
The material change reported is the execution of a new government contract. This agreement is designed to support the rapid identification and treatment of anti-viral diseases, specifically targeting Smallpox (a CDC Category A biothreat agent) and Adenovirus. The work will utilize computational biology to develop countermeasures for the USAF Special Operations Command.
Outlook, Risks, and Management Commentary
Management announced the agreement via a press release on September 27, 2005. The filing highlights the strategic importance of the project in maintaining combat readiness against biological threats. No specific financial guidance, risk factors, or contingencies regarding the contract's execution are detailed in this specific 8-K text.
Key Facts for Investor Verification
- Verify the specific milestones and payment terms within the attached Exhibit 10.1 agreement.
- Confirm the impact of this $3.2 million contract on the company's total projected revenue for the fiscal year.
- Review the press release (Exhibit 99.1) for additional details on the scope of work and timeline.
- Assess the company's current cash position to determine if external funding is required to fulfill the contract obligations.